Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

BACKGROUND: The inhaled lung-selective pan-Janus kinase inhibitor nezulcitinib had favourable safety and potential efficacy signals in part 1 of a phase 2 trial in patients with severe COVID-19, supporting progression to part 2. METHODS: Part 2 was a randomised, double-blind phase 2 study (NCT044028...

Descripción completa

Detalles Bibliográficos
Autores principales: Belperio, John, Nguyen, Tuan, Lombardi, David A, Bogus, Maxim, Moskalenko, Valentyn, Singh, Dave, Haumann, Brett, Bourdet, David L, Kaufman, Elad, Pfeifer, Nathan D, Thompson, Corbin G, Woo, Jacky, Moran, Edmund J, Saggar, Rajeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Critical Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357723/
https://www.ncbi.nlm.nih.gov/pubmed/37460276
http://dx.doi.org/10.1136/bmjresp-2023-001627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357723/
https://www.ncbi.nlm.nih.gov/pubmed/37460276
http://dx.doi.org/10.1136/bmjresp-2023-001627

Ejemplares similares